1. Introduction {#s0005}
===============

*Campylobacter* and non-typhoidal *Salmonella enterica* (NTS) are important agents of human bacterial gastroenteritis, representing over 30% (174.3 million) of diarrhoeal illnesses globally in 2010. While *Campylobacter* was the most common cause of bacterial gastroenteritis, NTS accounted for most of the deaths caused by a bacterial foodborne agent (over 59,000) and with the highest rank for disability adjusted life years amongst foodborne disease hazards in 2010 ([@bb0100]). Globally, foodborne disease burden is not equally distributed amongst the World Health Organisation (WHO) sub regions, with the greatest burden falling on the sub regions in Africa. Nevertheless, both *Campylobacter* and NTS (henceforth gastrointestinal (GI) infections) still pose a significant disease and economic burden in developed countries ([@bb0270], [@bb0155]).

Gastroenteritis caused by *Campylobacter jejuni*/*coli* and most serotypes of NTS are characterised by a self-limiting illness without the need for medical intervention. Yet, a subset of patients develop sequelae such as reactive arthritis (ReA), Reiter\'s Syndrome (RS), irritable bowel syndrome (IBS), Guillain-Barré Syndrome (GBS), Inflammatory Bowel Disease (IBD), Crohn\'s disease (CD) and ulcerative colitis (UC) ([@bb0010], [@bb0115], [@bb0120]).

Evidence on the factors predisposing some patients to sequelae development is limited, with only one study assessing the factors for development of IBS following enteric infection ([@bb0320]). The authors found that young age, prolonged fever, anxiety and depression were risk factors for post-infectious IBS, but they did not stratify those factors by the infecting pathogen. This is a drawback for burden of disease studies, as estimates of pathogen specific sequelae development are required for prioritization of public health interventions.

In a systematic review to assess the proportion of patients who develop chronic sequelae following GI infection, the authors found that study-level factors, such as diagnosis method for complications, follow-up period from infection to sequelae development, and study size, contribute to the reported incidence of ReA and IBS following *Campylobacter* and NTS infection ([@bb0115], [@bb0120]). However, the association of clinical factors such as proton pump inhibitors (PPI) usage and antibiotics in the development of chronic sequelae were not investigated. These drugs, which commonly increase risk of gastroenteritis, may also have a role in sequelae development due to changes to the gut microbiome and gastric pH that can favour pathogenic organisms ([@bb0035]).

In light of the existing gap in the evidence of factors contributing to sequelae development in patients with GI infections, this systematic review extends the previous reviews to assess the study- and patient-level risk factors associated with the development of complications following *Campylobacter* and NTS infections. Specifically, we assess whether use of PPI, treatment with antibiotics and clinical symptoms such as duration of diarrhea and fever are risk factors for the development of ReA, RS, IBS, GBS, IBD, CD and UC in adults and children with a *Campylobacter* or NTS infection.

2. Methods {#s0010}
==========

This systematic review and meta-analysis was conducted in line with the 'Meta-analysis of Observational Studies in Epidemiology' (MOOSE) guidelines ([@bb0305]). The protocol was registered on PROSPERO (CRD 42015026042).

2.1. Search Strategy and Selection Criteria {#s0015}
-------------------------------------------

We searched four electronic databases, PubMed, Agricola\[<http://agricola.nal.usda.gov>/\], EMBASE \[OvidSP\] (1974--2016 April 27) and CabDirect \[OvidSP\] (2000 to 2016 Week 15) for studies reporting sequelae of ReA, RS, IBS, GBS, IBD, CD and UC following gastrointestinal infections (*Campylobacter* and NTS). The search strategies consisted of a combination of relevant subject headings and free-text words in title and abstract for exposure and outcome. We restricted our search to studies published between 01 January 2011 and 29 April 2016 as this was an update and extension of the previous reviews with searches up to July 2011 ([@bb0115], [@bb0120]). The detailed search strategies and results for each of the databases are presented in Supplementary Table S1. Additional eligible studies on GI infections and associated sequelae were sought by reviewing the reference lists of identified articles. No language restrictions were applied during the search.

Two reviewers independently screened titles and abstracts for relevance. Studies were included if they were cohort (prospective or retrospective), case-control, surveillance report or cross-sectional studies, or outbreak investigations of people with *Campylobacter* or NTS infection, and reported the number or proportion of people who developed the sequelae of interest following *Campylobacter* or NTS infection. Studies were excluded if they: reported sequelae without evidence of a past exposure with *Campylobacter* or NTS infection; reported sequelae with only serological evidence of past exposure to pathogens; reported sequelae for multiple foodborne infections without a breakdown of the proportion/numbers by pathogen and sequelae; were case reports, case series or experimental studies such as randomised controlled trials and laboratory based studies. We added data for the period before July 2011 from the previous systematic reviews ([@bb0115], [@bb0120]) and extracted additional variables as required.

2.2. Data Extraction and Bias Assessment {#s0020}
----------------------------------------

Data were extracted independently by two reviewers (OE and MP) using a standardized form. Inconsistencies were resolved through a consensus process, with any disagreement resolved by a third reviewer, TF. Data coding and categorisation was in accordance with the previous reviews or otherwise stated (Supplementary Table S2) ([@bb0115], [@bb0120]). The primary outcome was the number of cases who developed the specific sequelae of interest divided by the total number of *Campylobacter* or NTS cases.

The Joanna Briggs Institute Prevalence Critical Appraisal Tool was adapted to evaluate the quality of each study ([@bb0205]). This tool was selected because of its flexibility to address the risk of bias across a variety of study designs, as commonly found in the study of incidence and prevalence. Initially a calibration exercise was performed by review members using a random sample of three studies. The items in the tool were applied to the selected studies to ensure consistency across reviewers and validity in assessing the risk of bias with this tool. Following this exercise two additional questions were included (Supplementary Table S3). Inconsistency was resolved through a consensus process.

2.3. Statistical Analysis {#s0025}
-------------------------

We performed meta-analysis in STATA version 13 (StataCorp LP) using "metaprop_one", a user written command for meta-analysing proportions ([@bb0210], [@bb0070]). Heterogeneity was quantified using the *I*^2^ measure ([@bb0110]). Where heterogeneity was high (*I*^2^ over 50%), no summary estimate was calculated.

It was possible to have multiple outcomes per study. Briefly, some studies reported multiple diagnostic methods for both pathogen and complication or multiple pathogen serotype/species. Each combination of pathogen diagnosis or sequelae diagnosis was considered as a separate outcome measure. Meta-analysis was performed using the most rigorous outcome measure based on the reference standard. For instance, where a study reported both laboratory-confirmed and probable diagnosis for a pathogen with multiple diagnostic methods for the sequelae of interest, such as self-reported diagnosis and further diagnosis by a specialist (rheumatologist for reactive arthritis), the combination of *Campylobacter*/NTS cases with a laboratory-confirmed diagnosis and the sequelae assessed by a specialist was used.

A priori subgroups to explore potential sources of heterogeneity were investigated based on relevant methodological characteristics (study design, study size, follow-up period and sequelae diagnosis) ([@bb0115], [@bb0120]) and clinical characteristics (healthcare facility visited, symptoms of GI infections, reported PPI and antibiotic usage), if data were available.

3. Results {#s0030}
==========

Primary searches identified 4133 references. On removal of duplicates and after screening, five studies met the inclusion criteria reporting ReA, RS, IBS and GBS following *Campylobacter* infection (*n* = 4) and ReA, RS and IBS following NTS infection (*n* = 3) ([@bb0020], [@bb0355], [@bb0240], [@bb0245], [@bb0350]). Data was extracted from all five studies and additional studies from the previous systematic reviews on ReA, RS, IBS and GBS following GI infections (*n* = 50). Hence 55 studies were included in the analysis ([Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}). No eligible studies on IBD, CD and UC were identified by our database search, so these sequelae are not considered further in this review.

[Table 2](#t0010){ref-type="table"} shows the characteristics of the included studies. The number of patients with GI infections varied widely (range 6 to 57,425 with *Campylobacter* and 24 to 34,664 with NTS infection) and represented all age groups. Studies reported diagnoses of the pathogen and complication according to standard practices for all cases of GI infections (87%, 48/55 and 75%, 41/55 respectively). Only 18% (10/55) reported adequate sample size calculation and, where response rate was low (49%, 27/55), only 15% (*n* = 4) adjusted for possible response bias in their analysis. An overall risk of bias score was not assigned as it was possible to have a high score (\> 70%, 8.5/12) without using a reliable method of pathogen and diagnosis for all patients.

Thirty-seven studies reported ReA following *Campylobacter* (*n* = 19) and NTS infections (*n* = 26) ([@bb0030], [@bb0025], [@bb0045], [@bb0050], [@bb0060], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0105], [@bb0225], [@bb0130], [@bb0140], [@bb0135], [@bb0145], [@bb0160], [@bb0165], [@bb0180], [@bb0215], [@bb0230], [@bb0235], [@bb0250], [@bb0255], [@bb0260], [@bb0275], [@bb0280], [@bb0290], [@bb0315], [@bb0325], [@bb0330], [@bb0340], [@bb0350], [@bb0355], [@bb0360], [@bb0035], [@bb0015], [@bb0055], [@bb0195]) in up to 63% of patients with either infection (Supplementary Table 4). The majority of studies reported ReA triggered by *Campylobacter* (*n* = 14) or NTS infection (*n* = 18) in \< 10% of patients with gastroenteritis. No overall summary of incidence of sequelae following gastroenteritis were calculated, as there was a high level of heterogeneity across studies (*I*^2^ \> 90%) ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}). The incidences of RS, IBS and GBS were reported in 5, 12, and 9 studies respectively ([Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"} and Table S4). \< 10% of patients with either infection developed RS in all studies. Incidence of IBS was reported in *Campylobacter* (0% to 18%) and NTS (0% to 38%) patients. GBS was less frequent with all but one study reporting an incidence of \< 2% following *Campylobacter* infection.

Only studies reporting incidence of ReA considered the use of PPI and antibiotics as potential factors contributing to sequelae development. One study assessing the use of PPI in the development of ReA following *Campylobacter* and NTS infection found a significant association after adjustment for age, sex and degree of urbanization (adjusted OR 2.9 (95% CI 1.4--6.1)) ([@bb0035]).

The prescription/usage of antibiotics was reported in 17 studies (*n* = 7 for *Campylobacter* and *n* = 11 for NTS) ([@bb0015], [@bb0030], [@bb0255], [@bb0060], [@bb0285], [@bb0045], [@bb0165], [@bb0095], [@bb0345], [@bb0350], [@bb0130], [@bb0225], [@bb0230], [@bb0235], [@bb0135], [@bb0140], [@bb0355]). Seven studies considered the risk of ReA development following antibiotics usage ([@bb0015], [@bb0030], [@bb0045], [@bb0165], [@bb0095], [@bb0135], [@bb0345]). Of these studies, increased risk of ReA development was observed following treatment of infection with antibiotics (class not provided) for *Campylobacter* and fluoroquinolones for NTS infection (*n* = 1 and 2, respectively) ([@bb0135], [@bb0045], [@bb0165]). Three studies found a protective effect in the use of antibiotics for NTS; however the findings were not statistically significant ([@bb0015], [@bb0030], [@bb0095]). The remaining study did not find any associated risk with antibiotic usage for either *Campylobacter* or NTS infection. Moreover the data were not reported in the study ([@bb0345]) ([Table 3](#t0015){ref-type="table"}). Studies assessing association of antibiotic treatment and development of ReA reported visit to a GP/Physician (*n* = 4) or accident and emergency/hospital (*n* = 3).

Clinical symptoms were scarcely reported by studies and, where available, studies used different definitions and thresholds for diarrhea and fever (data not shown). This prevented further analysis of the role of symptom severity in sequelae development.

For the methodological subgroup analysis, only consultation with a rheumatologist statistically reduced heterogeneity of studies within the "specialist" in *Campylobacter* and NTS triggered ReA ([Table 4A](#t0020){ref-type="table"}, [Table 4B](#t0025){ref-type="table"}, [Table 4C](#t0030){ref-type="table"}, [Table 4D](#t0035){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Follow-up may have contributed to heterogeneity in *Campylobacter* triggered IBS as studies within the 6-month follow-up stratum had a statistically significant reduction in heterogeneity (*I*^2^ = 24.2%) ([Table 4A](#t0020){ref-type="table"}, [Table 4B](#t0025){ref-type="table"}, [Table 4C](#t0030){ref-type="table"}, [Table 4D](#t0035){ref-type="table"}, [Fig. 6](#f0030){ref-type="fig"}). The only clinical characteristic considered in a subgroup analysis was the healthcare facility visited for the GI infection in those developing ReA and IBS. Studies reporting a "GP/Physician" visit for NTS infection were fairly homogenous (*I*^2^ = 2.0%), nonetheless high heterogeneity remained in this stratum for patients with *Campylobacter* triggered ReA ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}).

4. Discussion {#s0035}
=============

Previous systematic reviews considering incidence of ReA, RS, IBS and GBS conducted literature searches up until 2011 without assessing factors contributing to sequelae development. Five years after these searches were conducted, we only identified five new studies based on our inclusion criteria. We found that use of PPI and antibiotics may be possible factors associated with the development of ReA following GI infections. These factors were sparsely reported by studies and where information was available high heterogeneity (*I*^2^ \> 90%) prevented the pooling of data.

Despite the over prescription of PPI in both primary and secondary settings ([@bb0065]), only one study reported an association of PPI usage and ReA development in patients with gastroenteritis ([@bb0035]). The authors demonstrated that PPI usage was independent of a single nucleotide polymorphism (SNP) in interferon gamma (IFN-γ) in cases with *Campylobacter* and NTS infections and the development of reactive arthritis ([@bb0035]). IFN-γ is a cytokine crucial in the immune response against enteric infections. The combination of a SNP in IFN-γ with PPI usage could lead to increased susceptibility to enteric infections and subsequent prolonged or repeated episodes of GI infection. These sequential events may increase the susceptibility to reactive arthritis ([@bb0035]).

Of all the sequelae considered, only risk of reactive arthritis was assessed following antibiotic usage in cases of *Campylobacter* and NTS infection. The associated risk is not clear as the studies report elevated, decreased or no risk of ReA following GI infection. The association may be dependent on the dose and type of antibiotics, as evidenced in a systematic review ([@bb0005]) evaluating the risk of hemolytic uremic syndrome following the use of antibiotics in patients with shiga toxin producing *Escherichia coli* (STEC) infections. [@bb0005] showed that protein and cell wall synthesis class of antibiotics may be protective and improve recovery time and proposed a review of guidelines on contraindication of antibiotics for STEC infections.

Most gastroenteritis cases do not require treatment with antibiotics unless they are severe and occur in at risk groups i.e. elderly, children and those with underlying comorbidities. Due to insufficient information in the studies, we could not assess the potential reason for antibiotic treatment or the risk associated with sequelae development following antibiotic usage in a meta-analysis. Moreover, information on duration of treatment, dose of antibiotics, age and gender of all cases who received antimicrobial treatment were not available in all of the studies, thereby limiting any further comparisons or pooling of data.

Heterogeneity could not be explained by most of the subgroup analysis considered, except in the reported method of diagnosing reactive arthritis complication following *Campylobacter* and NTS infection, the type of healthcare facility visited for an NTS infection and follow-up period in *Campylobacter* triggered IBS. In studies reporting a visit to the GP/Physicians in cases of NTS infection the heterogeneity was significantly reduced (*I*^2^ = 2%). The three studies were all conducted in Finland, reported specialist diagnosis for reactive arthritis, had laboratory confirmation of the NTS infection and two assessed use of antibiotics in development of ReA in NTS patients. A GP/physician consultation may lead to a laboratory confirmed diagnosis of infection, prescription of antibiotics, and referral to a specialist; hence influencing the reported sequelae incidence. The small number of studies with inconsistent follow-up period from NTS infection to ReA development limits further interpretation of this finding.

Follow-up period may be crucial in the reported incidence of IBS following campylobacteriosis, due to a statistically significant reduction in heterogeneity in studies reporting a 6-month follow-up period, despite using different versions of Rome I, II and III criteria for diagnosis. The current gold-standard for IBS diagnosis is Rome III classification, which is symptom-based, requiring patients to be symptomatic both at 3 and 6 months after initial symptom onset ([@bb0150]) was used by only one study ([@bb0295]). Potential risk modifying factors in the development of IBS following gastroenteritis were not evaluated due to insufficient reporting and primary aim of included studies.

Data source may be a potential source of unexplained heterogeneity even though it was not significant in our subgroup analysis (data not shown). Using a combination of studies reporting outbreaks, population surveillance and hospital surveillance may have introduced additional heterogeneity. Outbreaks are usually caused by a single strain, while population surveillance identifies the circulating strains. In one of the studies included in this review, [@bb0350] used phenotypic methods to determine potential differences in the O antigens of different NTS serotypes circulating in a population surveillance. However no significant differences in the arthritogenicity of the serotypes to trigger ReA were identified ([@bb0350]). The precision of genomic methods, such as whole genome sequencing, may provide further insights into differing potential for bacterial strains to trigger sequelae.

Our study has a number of major strengths. Firstly, our study addresses an existing knowledge gap by assessing the available evidence on factors contributing to the development of sequelae following *Campylobacter* and NTS infection. This is important in understanding factors amenable to intervention. Secondly, our review highlights the need for investigators to consider remediable risk factors in sequelae development following GI infections.

The reliance of observational studies on "natural experiments" such as outbreaks makes them prone to low study quality and high level of bias and heterogeneity. Most outbreak investigations are set up as a rapid response to an emergency situation to determine the cause of the outbreak. Time constraints limits the opportunity to address secondary factors that may improve the overall evidence on GI triggered sequelae. Therefore, it was possible for a study to have a high quality score for the primary research but missing key items such as method of diagnosis of pathogen and sequelae, crucial for risk factor study. Thus, a quality criteria was not adopted for inclusion of studies for meta-analysis. Although heterogeneity was significantly reduced for studies reporting a specialist consultation for diagnosis of ReA following either *Campylobacter* or NTS infection, we did not report a pooled estimate. Specialist diagnosis was preceded by self-reported symptoms. Not all patients with symptoms were seen by a specialist. Further, the studies reported different follow-up times indicating different definitions of ReA were adopted.

Other limitations of our study include inconsistencies in the reporting of key features, such as age, definition of sequelae, and follow-up of gastroenteritis cases in included studies. The risk factors we considered were also sparsely reported. Further, unexplained sources of heterogeneity prevented the reporting of a summary statistic for factors contributing to sequelae development. These limit the application of estimates to the general population and made interpretation of results difficult.

In conclusion, the findings of this systematic review show that the factors contributing to sequelae development following GI infections remain unclear. This is a challenge for policy makers in targeting interventions to reduce the overall burden of GI infections. Researchers should consider reporting information that will improve the overall evidence of sequelae of GI infections when observational studies are conducted. Applying record linkage in following up patients\' health journey to study sequelae of GI infections may improve reporting of observational studies.

Furthermore, primary research in risk modifiers of gastroenteritis triggered sequelae and the potential for different bacterial strains to cause sequelae may address the knowledge gap in the relationship between pathogen and host.
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Results of all database searches, screening of titles and abstracts, full-text screening, additional references and selected studies.](gr1){#f0005}

![Forest plot of studies reporting incidence of *Campylobacter* triggered ReA stratified by healthcare facility.\
Studies reporting the incidence of reactive arthritis following *Campylobacter* infection stratified by the type of healthcare facility/practitioner visited/utilised. No summary estimate was calculated due to high heterogeneity across all studies (*I*^2^ \> 90%).](gr2){#f0010}

![Forest plot of studies reporting incidence of NTS triggered ReA stratified by healthcare facility.\
Studies reporting the incidence of reactive arthritis following non-typhoidal *Salmonella* infection stratified by the type of healthcare facility/practitioner visited/utilised. No summary estimate was calculated due to high heterogeneity across all studies (*I*^2^ \> 90%).](gr3){#f0015}

![Forest plot of studies reporting incidence of RS following NTS infection.\
Studies reporting the incidence of Reiter\'s syndrome following non-typhoidal *Salmonella* infection. No summary estimate was calculated due to high heterogeneity across all studies (*I*^2^ \> 90%).](gr4){#f0020}

![Forest plot of studies reporting incidence of IBS following *Campylobacter* infection stratified by follow-up period.\
Studies reporting the incidence of irritable bowel syndrome following *Campylobacter* infection stratified by the length of follow-up from infection to sequelae. No summary estimate was calculated due to high heterogeneity across all studies (*I*^2^ \> 90%).](gr5){#f0025}

![Forest plot of studies reporting incidence of IBS following NTS infection stratified by follow-up period.\
Studies reporting the incidence of irritable bowel syndrome following non-typhoidal *Salmonella* infection stratified by the length of follow-up from infection to sequelae. No summary estimate was calculated due to high heterogeneity across all studies (*I*^2^ \> 90%).](gr6){#f0030}

![Forest plot of studies reporting incidence of GBS following *Campylobacter* infection.\
Studies reporting the incidence of Guillain-Barré syndrome following *Campylobacter* infection No summary estimate was calculated due to high heterogeneity across all studies (*I*^2^ \> 90%).](gr7){#f0035}

###### 

Included studies by pathogen and sequelae reported.

Table 1

  Sequelae                   *Campylobacter*                                                                                                                                    NTS                                                                                                                                                                                                                             *Campylobacter* & NTS
  -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Reactive arthritis         [@bb0080], [@bb0125], [@bb0225], [@bb0290], [@bb0055], [@bb0230], [@bb0235], [@bb0195], [@bb0025], [@bb0090], [@bb0135], [@bb0280] and [@bb0355]   [@bb0085], [@bb0050], [@bb0325], [@bb0140], [@bb0160], [@bb0330], [@bb0260], [@bb0165], [@bb0060], [@bb0180], [@bb0360], [@bb0045], [@bb0255], [@bb0030], [@bb0095], [@bb0145], [@bb0130], [@bb0250], [@bb0015] and [@bb0350]   [@bb0215], [@bb0105], [@bb0035], [@bb0275], [@bb0315] and [@bb0345]
  Reiter\'s syndrome         None                                                                                                                                               [@bb0330], [@bb0165] and [@bb0045]                                                                                                                                                                                              [@bb0035] and [@bb0245]
  Irritable bowel syndrome   [@bb0300], [@bb0335], [@bb0040], [@bb0200], and [@bb0295]                                                                                          [@bb0185], [@bb0360] and [@bb0190]                                                                                                                                                                                              [@bb0105], [@bb0265], [@bb0315], and [@bb0240]
  Guillain Barré Syndrome    [@bb0175], [@bb0170], [@bb0105], [@bb0310], [@bb0315], [@bb0035], [@bb0365], [@bb0075] and [@bb0020]                                               None                                                                                                                                                                                                                            None

###### 

Study characteristics for complications following *Campylobacter* and non-typhoidal *Salmonella* infection.

Table 2

  First author, year        Country       Study design                            Data source                                         Outbreak source    Date_Data collection   Season          Age                 \% Female                             Complication
  ------------------------- ------------- --------------------------------------- --------------------------------------------------- ------------------ ---------------------- --------------- ------------------- ------------------------------------- ---------------------
  *Campylobacter* only                                                                                                                                                                                                                                    
  [@bb0020]                 New Zealand   Prospective population surveillance     Hospital records                                    N.A.               1995--2008             All             All ages            N.R.                                  GBS
  [@bb0025]                 Sweden        Prospective outbreak                    Outbreak in community                               Unknown            1981                   Autumn          Adults              56%                                   ReA
  [@bb0040]                 England       Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               1999--2002             Various         Adult               N.R.                                  IBS
  [@bb0055]                 Scotland      Retrospective outbreak                  Outbreak in community                               Food - dairy       1979                   Winter          N.R.                N.R.                                  ReA
  [@bb0075]                 Canada        Prospective outbreak                    Outbreak in community                               Food - vegetable   2008                   Autumn          All ages            51%                                   GBS
  [@bb0080]                 England       Retrospective population surveillance   Surveillance of population (sporadic or outbreak)   N.A.               1978                   All             All ages            N.R.                                  ReA
  [@bb0090]                 Finland       Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               1997--1998             All             All ages            59%                                   ReA
  [@bb0125]                 Finland       Unknown                                 Surveillance of population (sporadic or outbreak)   N.A.               1978--1979             All             N.R.                N.R.                                  ReA
  [@bb0135]                 Denmark       Retrospective population surveillance   Surveillance of population (sporadic or outbreak)   N.A.               1997--2000             All             Adults              57%                                   ReA
  [@bb0175]                 Sweden        Retrospective outbreak                  Outbreak in community                               Waterborne         1980, 1994, 1995       Various         N.R.                N.R.                                  GBS
  [@bb0170]                 Sweden        Retrospective population surveillance   Disease registry                                    N.A.               1987--1995             All             All ages            N.R.                                  GBS
  [@bb0195]                 Norway        Retrospective outbreak                  Outbreak in community                               Waterborne         Pre-1990               Spring/summer   All ages            48%                                   ReA
  [@bb0200]                 New Zealand   Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               2002--2003             Various         Adults              N.R.                                  IBS
  [@bb0230]                 Finland       Prospective hospital surveillance       Hospital records                                    N.A.               1978--1981             All             All ages            47%                                   ReA
  [@bb0225]                 Finland       Prospective hospital surveillance       Hospital records                                    N.A.               1978--1980             All             All ages            46%                                   ReA
  [@bb0235]                 Finland       Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               1978--1981             All             N.R.                N.R.                                  ReA
  [@bb0280]                 Finland       Cross sectional                         Surveillance of population (sporadic or outbreak)   N.A.               2002                   Summer          All ages            48%                                   ReA
  [@bb0290]                 UK            Prospective                             Hospital records                                    N.A.               1979                   Various         N.R.                N.R.                                  ReA
  [@bb0295]                 New Zealand   Prospective                             Surveillance of population (sporadic or outbreak)   N.A.               Pre-2006               All             Adults              N.R.                                  IBS
  [@bb0300]                 UK            Prospective population surveillance     Hospital records                                    N.A.               Pre-2000               All             Adult               N.R.                                  IBS
  [@bb0310]                 UK            Retrospective population surveillance   Disease registry                                    N.A.               1991--2001             All             N.R.                N.R.                                  GBS
  [@bb0335]                 UK            Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               1997                   Spring/summer   Adults              N.R.                                  IBS
  [@bb0355]                 Finland       Retrospective outbreak                  Outbreak in community                               Waterborne         2007                   Winter          All ages            73%                                   ReA
  [@bb0365]                 China         Retrospective population surveillance   Hospital records                                    N.A.               2000--2006             All             Children            30%                                   GBS
                                                                                                                                                                                                                                                          
  NTS only                                                                                                                                                                                                                                                
  [@bb0015]                 Spain         Prospective outbreak                    Outbreak in community                               Food - meat        2005                   Summer          All ages            49.7%                                 ReA
  [@bb0030]                 Canada        Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               1999--2000             All             All ages            53.0%                                 ReA
  [@bb0045]                 USA           Prospective outbreak                    Outbreak in community                               Food - meat        1994                   Autumn/winter   Adults              58.5%                                 ReA, Reiter\'s
  [@bb0050]                 Scotland      Prospective outbreak                    Outbreak in community                               Food - dairy       1981                   Autumn          All ages            47.8%                                 ReA
  [@bb0060]                 Finland       Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               1998--1999             All             NR                  53.0%                                 ReA
  [@bb0085]                 Sweden        Retrospective outbreak                  Outbreak in community                                                  1974                   N.R.            Adults              N.R.                                  ReA
  [@bb0095]                 Finland       Prospective outbreak                    Outbreak in community                               Unknown            1999                   Spring/summer   Adults & Children   56.9%                                 ReA
  [@bb0130]                 Australia     Retrospective outbreak                  Outbreak in community                               Food - vegetable   1999                   Various         All ages            48.3%                                 ReA
  [@bb0140]                 Finland       Retrospective outbreak                  Outbreak in community                               Food - other       1990                   Spring          Adults              44.4%                                 ReA
  [@bb0145]                 Denmark       Prospective outbreak                    Outbreak in community                               Food - other       1999                   Winter          Adults              56.0%                                 ReA
  [@bb0160]                 Finland       Prospective outbreak                    Outbreak in community                               Food - vegetable   1992                   Autumn          All ages            62.2%                                 ReA
  [@bb0165]                 Finland       Prospective outbreak                    Outbreak in community                               Food - vegetable   1994                   Spring          All ages            68.1%                                 ReA & Reiter\'s
  [@bb0180]                 Australia     Prospective outbreak                    Outbreak in community                               Food - meat        1997                   Spring          All ages            51.0%                                 ReA
  [@bb0185]                 UK            Prospective outbreak                    Outbreak in community                               Food- other        Pre-1994               N.R.            N.R.                65.8%                                 IBS
  [@bb0190]                 Spain         Prospective outbreak                    Outbreak in community                               Food - dairy       2002                   Summer          Adults              55.3%                                 IBS
  [@bb0250]                 Canada        Retrospective outbreak                  Outbreak in community                               Food - vegetable   2005                   Autumn/winter   Adults              71.2%                                 ReA
  [@bb0255]                 Germany       Prospective outbreak                    Outbreak in community                               Food - dairy       1998                   Winter          Children            N.R.                                  ReA
  [@bb0260]                 USA           Retrospective outbreak                  Outbreak in community                               Unknown            1993                   Summer          NR                  N.R.                                  ReA
  [@bb0330]                 Canada        Retrospective outbreak                  Outbreak in community                               Food - meat        1990                   Spring          NR                  N.R.                                  ReA
  [@bb0325]                 Canada        Prospective outbreak                    Outbreak in community                               Food - meat        Pre-1992               N.R.            Adults              94.5%                                 ReA
  [@bb0350]                 Finland       Prospective population surveillance     Surveillance of population (sporadic or outbreak)   NA                 2003--2004             Various         All ages            60.1%                                 ReA
  [@bb0360]                 Switzerland   Prospective outbreak                    Outbreak in community                               Food - meat        1993                   Autumn          All ages            37.2%                                 IBS & ReA
                                                                                                                                                                                                                                                          
  *Campylobacter* and NTS                                                                                                                                                                                                                                 
  [@bb0035]                 Netherlands   Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               2002--2003, 2005       All             NR                  N.R.                                  GBS, ReA, Reiter\'s
  [@bb0105]                 Denmark       Retrospective population surveillance   Disease registry                                    N.A.               1991--1999             All             All ages            52%                                   GBS, IBS, ReA
  [@bb0215]                 Denmark       Retrospective hospital surveillance     Hospital records                                                       1991--1993             All             All ages            N.R.                                  ReA
  [@bb0245]                 USA           Retrospective population surveillance   Disease registry                                    N.A.               1998 to 2009           All             Adults              N.R.                                  Reiter\'s
  [@bb0240]                 USA           Retrospective population surveillance   Disease registry                                    N.A.               1998 to 2009           All             Adults              N.R.                                  IBS
  [@bb0265]                 USA & Italy   Prospective population surveillance     Hospital records                                    N.A.               2006                   Various         Children            N.R.                                  IBS
  [@bb0275]                 Denmark       Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               2002--2003             All             Adults              57%                                   ReA
  [@bb0315]                 Sweden        Retrospective population surveillance   Surveillance of population (sporadic or outbreak)   N.A.               1997--2004             All             All ages            *Campylobacter* - 47% NTS - 50.6%     GBS, IBS, ReA
  [@bb0345]                 USA           Prospective population surveillance     Surveillance of population (sporadic or outbreak)   N.A.               2002--2004             All             All ages            *Campylobacter* - 46.9% NTS - 56.0%   ReA

N.A. -- not applicable; N.R. -- not reported.

###### 

Risk of developing ReA following prescription/usage of antibiotics in Campylobacter and NTS patients stratified by healthcare facility accessed.

Table 3

  Author_year                                 Pathogen                 No. with pathogen   Antibiotics usage N (%)                    Antibiotics                         Proportion of ReA vs. non-ReA using antibiotics
  ------------------------------------------- ------------------------ ------------------- ------------------------------------------ ----------------------------------- ---------------------------------------------------------------------------------------------------------------
  Visited general practitioner/physician                                                                                                                                  
  [@bb0135]                                   *Campylobacter*          173                 56 (32)                                    N.R.                                56% with ReA vs. 26% non-ReA; *p* = 0.03[a](#tf0005){ref-type="table-fn"}, [d](#tf0020){ref-type="table-fn"}
  [@bb0015]                                   *S*. Hadar PT2           155                 57 (38)[b](#tf0010){ref-type="table-fn"}   Fluoroquinolones                    aRR[c](#tf0015){ref-type="table-fn"} 0.43; 95% CI 0.17--1.08
  [@bb0095]                                   *S*. Typhimurium DT193   63                  32 (63)[b](#tf0010){ref-type="table-fn"}   Fluoroquinolones                    0% with ReA vs. 16% no ReA; *p* = 0.056
  [@bb0165]                                   *S*. Bovismorbificans    191                 78 (41)                                    Fluoroquinolones                    59% with ReA vs. 35% non-ReA; *p* = 0.021[a](#tf0005){ref-type="table-fn"}, [d](#tf0020){ref-type="table-fn"}
                                                                                                                                                                          
  Visited accident & emergency/hospitalised                                                                                                                               
  [@bb0045]                                   *S*. Enteritidis         217                 66 (30)                                    Fluoroquinolones                    RR 1.6; 95% CI 1.1--2.5[a](#tf0005){ref-type="table-fn"}
  [@bb0345]                                   NTS                      1356                365 (27)                                   Quinolone, β-lactam and macrolide   No associated risk (data not reported)
  [@bb0345]                                   *Campylobacter*          2384                1978 (83)                                  Quinolone, β-lactam and macrolide   No associated risk (data not reported)
                                                                                                                                                                          
  Visit of healthcare facility not reported                                                                                                                               
  [@bb0030]                                   *S*. Typhimurium         61                  28 (46)                                    N.R.                                OR 0.29; 95% CI 0.07--1.18

Antibiotics information not available for all with gastroenteritis.

Adjusted relative risk.

Significant results.

Chi-squared test in comparison of proportion.

###### 

Subgroup meta-analysis for studies reporting development of reactive arthritis following *Campylobacter* infection by sequelae diagnosis, follow-up period, study size and healthcare facility visited.

Table 4A

  Variable                                                  *I*^2^   Number of studies
  --------------------------------------------------------- -------- -------------------
  *Sequelae diagnosis*                                               
  Physician/medical records                                 95.6%    6
  Self-reported disease status                              97.0%    6
  Self-reported disease status based on a validated scale   --       1
  Specialist[a](#tf0025){ref-type="table-fn"}               48.6%    2
  Combination                                               0.0%     3
  Not reported                                              --       1
                                                                     
  *Follow-up period*                                                 
  \< 3 months                                               97.0%    8
  3 months                                                  --       1
  \> 3 months \< 1 year                                     --       --
  1 year                                                    95.6%    3
  \> 1 year                                                 97.8%    2
  Not reported                                              56.4%    5
                                                                     
  *Study size*                                                       
  Extra small (*n* \< 100)                                  95.3%    7
  Small (101--500)                                          86.3%    7
  Medium (501--1000)                                        --       1
  Large (1001--10,000)                                      97.70%   2
  Extra-large (\> 10.000)                                   99.20%   2
                                                                     
  *Healthcare facility visited*                                      
  GP/physician                                              --       1
  GP/hospitalised                                           --       --
  A&E/hospitalised                                          --       1
  Hospitalised                                              97.8%    7
  Not reported                                              98.8%    10

Heterogeneity significantly reduced (*I*^2^ \< 50%).

###### 

Subgroup meta-analysis for studies reporting development of reactive arthritis following NTS infection by sequelae diagnosis, follow-up period, study size and healthcare facility visited.

Table 4B

  Variable                                                  *I*^2^   Number of studies
  --------------------------------------------------------- -------- -------------------
  *Sequelae diagnosis*                                               
  Physician/medical records                                 97.7%    9
  Self-reported disease status                              96.8%    9
  Self-reported disease status based on a validated scale   --       1
  Specialist[a](#tf0030){ref-type="table-fn"}               41.2%    6
  Combination                                               --       1
  Not reported                                              --       1
                                                                     
  *Follow-up period*                                                 
  \< 3 months                                               97.3%    10
  3 months                                                  81.3%    5
  \> 3 months \< 1 year                                     93.5%    4
  1 year                                                    97.8%    2
  \> 1 year                                                 95.3%    2
  Not reported                                              97.7%    4
                                                                     
  *Study size*                                                       
  Extra small (*n* \< 100)                                  58.8%    7
  Small (101--500)                                          95.6%    16
  Medium (501--1000)                                        96.1%    1
  Large (1001--10,000)                                      --       1
  Extra-large (\> 10.000)                                   99.80%   1
                                                                     
  *Healthcare facility visited*                                      
  GP/physician[a](#tf0030){ref-type="table-fn"}             2.0%     3
  GP/hospitalised                                           --       1
  A&E/hospitalised                                          99.9%    2
  Hospitalised                                              91.7%    5
  Not reported                                              98.8%    20

Heterogeneity significantly reduced (*I*^2^ \< 50%).

###### 

Subgroup meta-analysis for studies reporting development of irritable bowel syndrome following *Campylobacter* infection by sequelae diagnosis, follow-up period, study size and healthcare facility visited.

Table 4C

  Variable                                                  *I*^2^   Number of studies
  --------------------------------------------------------- -------- -------------------
  *Sequelae diagnosis*                                               
  Physician/medical records                                 99.6%    3
  Self-reported disease status based on a validated scale   63.2%    6
                                                                     
  *Follow-up period*                                                 
  3 months                                                  --       1
  \> 3 months \< 1 year[⁎](#tf1000){ref-type="table-fn"}    24.2%    4
  1 year                                                    99.4%    3
  Not reported                                              --       1
                                                                     
  *Study size*                                                       
  Extra small (*n* \< 100)                                  87.7%    3
  Small (101--500)                                          --       1
  Medium (501--1000)                                        92.2%    4
  Extra large (\> 10.000)                                   99.90%   2

Heterogeneity significantly reduced (*I^2^ \< 50%*).

###### 

Subgroup meta-analysis for studies reporting development of irritable bowel syndrome following NTS infection by sequelae diagnosis, follow-up period, study size and healthcare facility visited.

Table 4D

  Variable                                                  *I*^2^   Number of studies
  --------------------------------------------------------- -------- -------------------
  *Sequelae diagnosis*                                               
  Physician/medical records                                 99.6%    3
  Self-reported disease status                              --       1
  Self-reported disease status based on a validated scale   87.3%    3
                                                                     
  *Follow-up period*                                                 
  \> 3 months \< 1 year                                     99.8%    2
  1 year                                                    99.5%    4
  Not reported                                              --       1
                                                                     
  *Study size*                                                       
  Extra small (*n* \< 100)                                  87.7%    3
  Small (101--500)                                          --       1
  Medium (501--1000)                                        --       1
  Extra-large (\> 10.000)                                   99.20%   2
                                                                     
  *Healthcare facility*                                              
  Hospitalised                                              99.70%   2
  Not reported                                              98.8%    5
